Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib for autoimmune hemolytic anemia in patients with CLL/SLL or CLL-like monoclonal B-cell lymphocytosis
2023-509793-38-00Phase 2Authorised
- Sponsor
- GIMEMA
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in autoimmune haemolytic anaemia (AIHA), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and monoclonal B cell lymphocytosis (MBL), sponsored by GIMEMA. Primary endpoint: AIHA overall response rate after 6 cycles. Planned start Nov 2023; status: authorised.
02
Drugs
ibrutinib
03
Conditions
autoimmune haemolytic anaemia (AIHA)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)monoclonal B cell lymphocytosis (MBL)
Beyond the preview
Go deeper on 2023-509793-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509793-38-00.